Premium
The emerging role of anti‐ CD 25 directed therapies as both immune modulators and targeted agents in cancer
Author(s) -
Flynn Michael J.,
Hartley John A.
Publication year - 2017
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.14770
Subject(s) - immunotoxin , immune system , cancer research , immunology , cancer , antibody , immunotherapy , medicine , biology , monoclonal antibody
Summary CD 25 (also termed IL 2 RA ) forms one component of the high‐affinity heterotrimeric interleukin 2 ( IL 2) receptor on activated T cells. Its affinity for IL 2 and cellular function are tightly regulated and vary in different cell types. The high frequency of CD 25 on the surface of many different haematological tumour cells is now well established and, apart from its prognostic significance, CD 25 may be present on leukaemic stem cells and enable oncogenic signalling pathways in leukaemic cells. Additionally, high CD 25 expression in activated circulating immune cells and Tregs is a factor that has already been exploited by IL 2 immunotherapies for treatment of tumours and autoimmune disease. The relative clinical safety and efficacy of administering anti‐ CD 25 radioimmunoconjugates and immunotoxins in various haematological tumour indications has been established and clinical trials of a novel CD 25‐directed antibody drug conjugate are underway.